TD Cowen analyst Gary Taylor raised the firm’s price target on Amedisys to $101 from $84 and keeps a Market Perform rating on the shares. The firm updated its model for Q2 results which exceeded estimates for hopsice EBITDA and the proposed HHA MDCR FFS payment cut for 2024.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AMED:
- Option Care Health price target raised to $41 from $34 at Barrington
- Amedisys reports Q2 adjusted EPS $1.37, consensus $1.09
- Amedisys Reports Second Quarter 2023 Financial Results
- AmEx downgraded, Keurig Dr Pepper upgraded: Wall Street’s top analyst calls
- Amedisys downgraded to Hold from Buy at Jefferies